Tissium, a French biotech company, has recently secured €50m in funding to advance its tissue repair platform for commercial use. The funding round was led by a group of investors, including Bpifrance, the European Investment Bank, and the European Investment Fund.
Tissium’s platform is based on a proprietary technology called Tissue Factory, which enables the production of fully synthetic, biocompatible tissues that can be used to repair damaged or diseased tissues in the body. The technology is designed to overcome the limitations of traditional tissue engineering approaches, which often rely on the use of animal-derived materials or require complex and expensive manufacturing processes.
The Tissue Factory technology uses a combination of synthetic polymers and bioactive molecules to create a scaffold that mimics the structure and function of natural tissues. The scaffold is then seeded with cells from the patient’s own body, which grow and differentiate into the desired tissue type. The resulting tissue can be implanted into the patient without the risk of rejection or immune system reactions.
Tissium’s platform has already been used in preclinical studies to repair a variety of tissues, including skin, cartilage, and blood vessels. The company is now focused on advancing its technology for commercial use, with a particular emphasis on developing products for the cardiovascular and orthopedic markets.
The funding secured by Tissium will be used to support the company’s ongoing research and development efforts, as well as to expand its manufacturing capabilities and prepare for regulatory approval of its products. The company also plans to establish partnerships with other companies and academic institutions to further advance its technology and explore new applications.
The Tissium platform has the potential to revolutionize the field of tissue engineering and regenerative medicine by providing a scalable and cost-effective solution for repairing damaged tissues. With the support of its investors and partners, Tissium is well-positioned to bring its technology to market and make a significant impact on the lives of patients around the world.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Minting the Future w Adryenn Ashley. Access Here.
- Buy and Sell Shares in PRE-IPO Companies with PREIPO®. Access Here.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Source: https://platohealth.ai/tissium-bags-e50m-to-commercialise-tissue-repair-platform/
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States The Food and...